A single-step sizing and radiofrequency ablation catheter for circumferential ablation of Barrett's esophagus: Results of a pilot study by Belghazi, K. (K.) et al.
Original Article
A single-step sizing and radiofrequency ablation
catheter for circumferential ablation of Barrett’s
esophagus: Results of a pilot study
K Belghazi1, RE Pouw1, CMT Sondermeijer1, SL Meijer2, EJ Schoon3, AD Koch4,
BLAM Weusten5 and JJGHM Bergman1
Abstract
Background: The 360 Express balloon catheter (360 Express) has the ability to self-adjust to the esophageal lumen, ensuring
optimal tissue contact.
Objective: The objective of this article is to evaluate the efficacy and safety of the 360 Express for radiofrequency ablation
(RFA) treatment of Barrett’s esophagus (BE).
Methods: BE patients with low-grade dysplasia (LGD), high-grade dysplasia (HGD) or early cancer (EC) were included. Visible
lesions were removed by endoscopic resection (ER) prior to RFA. RFA was performed with the 360 Express using the standard
ablation regimen (12J/cm2–clean–12J/cm2). Primary outcome: BE regression percentage at three months. Secondary outcomes:
procedure time, adverse events, complete eradication of dysplasia (CE-D) and intestinal metaplasia (CE-IM).
Results: Thirty patients (median BE C4M6) were included. Eight patients underwent ER prior to RFA. Median BE regression:
90%. Median procedure time: 31 minutes. Adverse events (13%): laceration (n¼ 1); atrial fibrillation (n¼ 1); vomiting and
dysphagia (n¼ 1); dysregulated diabetes (n¼ 1). After subsequent treatment CE-D and CE-IM was achieved in 97% and
87%, respectively. In 10% a stenosis developed during additional treatment requiring a median of one dilation.
Conclusion: This study shows that circumferential RFA using the 360 Express may shorten procedure time, while maintaining
efficacy compared to standard circumferential RFA.
Keywords
Barrett’s esophagus, endoscopic treatment, radiofrequency ablation, low-grade dysplasia, high-grade dysplasia, early
cancer
Received: 4 January 2018; accepted: 26 February 2018
Key summary
What is known on this subject?
. Radiofrequency ablation (RFA) has proven to be highly eﬀective and safe in the treatment of dysplastic
Barrett’s esophagus (BE).
. Circumferential RFA (c-RFA) with the Barrx 360 system using the standard ablation regimen results in a
median procedure duration of 39 minutes and in median 83% BE regression after a single procedure.
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What are the signiﬁcant and/or new ﬁndings of this study?
. C-RFA with the 360 Express using the standard ablation regimen results in shorter procedures (median 31
minutes), while maintaining eﬃcacy when compared to c-RFA using the Barrx 360 system (90%).
Introduction
Currently advised therapy for patients with Barrett’s
esophagus (BE) and conﬁrmed low-grade dysplasia
(LGD), high-grade dysplasia (HGD) or mucosal
cancer consists of endoscopic resection (ER) for visible
abnormalities, followed by radiofrequency ablation
(RFA) to eradicate all Barrett’s mucosa. This
approach has shown to be highly eﬀective and safe.
Complete eradication of dysplasia is achieved in 96%
to 100% and complete eradication of intestinal meta-
plasia in 93% to 96% of patients.1–3 Most patients
undergo primary circumferential RFA (c-RFA) with
a balloon-based electrode, followed by additional
focal RFA sessions using a cap-based electrode.
Originally, a circumferential ablation procedure started
with the introduction of a sizing balloon to measure the
esophageal inner diameter (EID) at multiple levels.
Subsequently, the sizing balloon was removed and an
ablation balloon with the appropriate diameter was
selected and introduced. The ablation balloon was
available in ﬁve sizes ranging from 18mm to 31mm,
and a diameter smaller than the smallest measured
diameter was selected to minimize risk of laceration
and perforation. A disadvantage of this approach was
the need for multiple introductions with the sizing cath-
eter, ablation catheter and endoscope. Furthermore,
one ablation catheter with a ﬁxed diameter was used
to ablate the entire Barrett’s segment, although the
EID may diﬀer within the same patient. By incorpor-
ating the sizing balloon and the ablation balloon into a
single device, the use of a separate sizing balloon is
eliminated, and a compliant balloon will adjust to dif-
ferent EIDs resulting in optimal mucosal contact with
the electrode.
The new BarrxTM 360 Express RFA balloon catheter
(360 Express) is a circumferential balloon catheter that
contains a 4 cm long bipolar electrode that is wrapped
around a balloon and features the ability to self-adjust
to the esophageal lumen.
We hypothesized that by incorporating the sizing
and ablation balloon into a single device, procedure
time will be shortened without aﬀecting the safety
of the procedure. The eﬃcacy of the procedure
may be increased by the improved adjustment of
the ablation balloon catheter to the esophageal
mucosa. The aim of this pilot study was to evaluate
the eﬃcacy and safety of the 360 Express RFA bal-
loon catheter.
Materials and methods
Study design
This was an uncontrolled, prospective, multicenter pilot
study conducted at four collaborating Dutch tertiary
referral centers: Academic Medical Center Amsterdam,
Catharina Hospital Eindhoven, Erasmus Medical Center
Rotterdam, and St. Antonius Hospital Nieuwegein.
Study data were collected on standardized case record
forms and entered into a central database.
Patient selection
Patients were eligible if they met all of the following
inclusion criteria:
(a) age 18 to 85 years;
(b) BE segment between 2 cm and 10 cm at baseline,
prior to any ER;
(c) biopsy-proven LGD, HGD or cancer conﬁrmed by
an expert pathologist;
(d) in case of prior ER for early cancer or visible
lesions, the resection had to be limited to <2 cm in
length and <50% of the circumference; and
(e) written informed consent.
Patients were excluded if they had any of the follow-
ing exclusion criteria:
(a) prior endoscopic ablation treatment;
(b) signiﬁcant esophageal stenosis preventing passage
of a diagnostic endoscope or any prior endoscopic
dilation for esophageal stenosis;
(c) in case of prior ER: positive vertical resection margins,
deep submucosal invasion (>T1sm1), poorly or undif-
ferentiated cancer, or lymphatic/vascular invasion;
(d) in case of prior ER: no invasive cancer in any of the
biopsies obtained from residual BE;
(e) an interval of> 6months between the last high-resolu-
tion endoscopy with biopsies and the RFA treatment,
or an interval <6 weeks between ER and RFA; and
(f) contraindications for RFA treatment.
Work-up endoscopy prior to RFA
Patients underwent a high-resolution endoscopy within
six months prior to c-RFA treatment. Biopsies were
obtained according to the Seattle protocol (4Q/2 cm).
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In case of visible lesions, ER was performed using
the ER cap technique (Olympus GmbH; Hamburg,
Germany) or multiband mucosectomy (Duette MBM
system, Cook Endoscopy, Limerick, Ireland).
Immediately after the ER or during a separate endos-
copy, biopsies were obtained from the residual Barrett’s
segment (4Q/2 cm). In case no cancer was found in the
residual BE, the c-RFA procedure was scheduled at
least six weeks after ER.
RFA treatment
Study device Circumferential ablation was performed
using the BarrxTM 360 Express RFA balloon catheter
(Medtronic, Sunnyvale, CA, USA) (Figure 1). Details
on the 360 Express system are provided in Appendix A.
RFA procedure Procedures were performed under con-
scious sedation with midazolam and/or fentanyl or
under monitored deep sedation with propofol. Prior
to ablation, the esophagus was inspected using white-
light high-resolution endoscopy (WLE) and narrow-
band imaging (NBI) to exclude presence of (residual)
visible abnormalities. The extent of columnar-lined
esophagus was documented according to the Prague
C&M classiﬁcation4 and still images with WLE and
NBI were taken at 1 cm intervals. Then, a guidewire
was introduced and the endoscope removed. The 360
Express was introduced, followed by the endoscope.
Under endoscopic visualization, the balloon was pos-
itioned at the proximal end of the Barrett’s segment.
Under visual control the BE was ablated (12 J/cm2)
working from proximally to distally using visual repos-
itioning. A small overlap (i.e.<1 cm) between ablation
zones was allowed. After the ﬁrst ablation pass,
the endoscope was removed followed by removal
of the ablation catheter. The coagulum was cleaned
oﬀ the balloon catheter. The endoscope was reintro-
duced to clean the ablation zone, by irrigation and
scraping oﬀ coagulum using the rim of a distal attach-
ment cap placed on the tip of the endoscope. Then, the
guidewire was reintroduced, the endoscope removed
and the ablation catheter and endoscope were reintro-
duced to repeat ablation (12J/cm2).
Post-ablation care All study patients received esomepra-
zole 40mg twice a day (or an equivalent dose of proton
pump inhibitor) as a maintenance dosage during the
study. In addition patients were prescribed ranitidine
300mg at bedtime and 5ml sucralfate suspension for
a period of two weeks following RFA.
Follow-up after treatment
Three months after the c-RFA procedure, the ﬁrst post-
treatment endoscopy was performed. Still images with
WLE and NBI were obtained from every 1 cm of
the original BE segment, to assess the percentage of
endoscopically visible regression of BE and presence
of esophageal stenosis. Biopsies were not routinely
obtained during this session. Further treatment was
performed according to standard guidelines. In general,
additional focal RFA sessions using the standard abla-
tion regimen (2 15 J/cm2 – clean – 2 15 J/cm2) or a
Figure 1. Wrap/unwrap electrode design of the 360 Express RFA balloon catheter.
Belghazi et al. 3
simpliﬁed ablation regimen (3 15 J/cm2 – no clean or
3 12 J/cm2 – no clean) were scheduled approximately
every three months until complete endoscopic eradica-
tion of all BE was achieved. After complete endoscopic
and histological eradication of intestinal metaplasia
(CE-IM) and dysplasia (CE-D), patients were sched-
uled for further follow-up.
Histological evaluation
All biopsies and ER specimens were routinely pro-
cessed and evaluated by a local gastrointestinal expert
pathologist. All biopsies were assessed for IM and
grade of dysplasia according to the Vienna classiﬁca-
tion.5 ER specimens were evaluated for dysplasia,
tumor inﬁltration depth, diﬀerentiation, presence of
lymphatic or vascular invasion, and radicality.
Outcome parameters
Primary outcome Percentage of endoscopically visual
surface regression of BE epithelium at three months.
The percentage of BE regression was independently
scored by two endoscopists (E.J.S. and B.L.A.M.W.)
who reviewed the endoscopic images that were taken
from every cm of the original BE segment immediately
prior to the initial c-RFA procedure and during the ﬁrst
post-treatment endoscopy at three months.
Deﬁnitions of all outcome parameters are summar-
ized in Table 1.
Secondary outcomes
1. Duration of the 360 Express ablation procedure.
2. Adverse events related to the 360 Express ablation
procedure.
3. Rate of CE-D and CE-IM at the end of the treat-
ment phase.
4. Number of patients with a stenosis requiring an
intervention at any time during the treatment phase.
Statistical analysis and ethical considerations
Because this was a pilot study no sample size calcula-
tion was performed.
Data analysis was performed using SPSS statistical
software (version 24, SPSS Inc, Chicago, IL, USA).
The mean ( standard deviation) was used to describe
variables with a normal distribution and the median (and
interquartile range (IQR)) for variables with a skewed
distribution. The study was approved by the institutional
review board (IRB) of the Academic Medical Center
Amsterdam (date of approval: September 24, 2014).
The study protocol conforms to the ethical guidelines
of the 1975 Declaration of Helsinki as reﬂected in a
priori approval by the IRB. Written informed consent
was obtained from all participants. This study was regis-
tered in the ISRCTN registry (www.isrctn.com, number:
ISRCTN38642364).
Results
Patients
Between October 2014 and December 2014, 30 consecu-
tive patients were included. Baseline characteristics are
shown in Table 2.
Primary outcome
The median BE surface regression at three months was
90% (IQR 77–95) (Figure 2).
In one patient a consensus meeting was required
because the BE regression diﬀered 30% between the
two endoscopists (60% versus 90%). The consensus
BE regression was 80%.
Secondary outcomes
1. Duration of the 360 Express procedure The median total
procedure time was 31 minutes (IQR 28–38). The
median ablation time was 20 minutes (IQR 17–25).
2. Adverse events No severe adverse events related to the
use of the 360 Express device were observed. In four
patients (13%) a mild or moderate adverse event
occurred: mucosal laceration (n¼ 1); asymptomatic
atrial ﬁbrillation (n¼ 1); vomiting and dysphagia
(n¼ 1); dysregulated diabetes (n¼ 1). Details of these
adverse events are described in Appendix B.
Esophageal scarring None of the patients developed a
symptomatic stenosis after initial RFA treatment with
the 360 Express. Although not prespeciﬁed for this
study, the endoscopists noted pronounced esophageal
scarring in 7/30 patients (23%) at the three-month
follow-up endoscopy (Figure 3). In 3/7 patients ER
was performed prior to RFA treatment. There were
no problems passing a diagnostic gastroscope in any
of these patients.
3. Rate of CE-D and CE-IM at the end of the treatment
phase By December 2016, 28/30 patients completed
treatment. In two patients further endoscopic treatment
was discontinued after initial ablation with the 360
Express because of comorbidity. In the ﬁrst patient,
biopsies at the last endoscopy showed IM without dys-
plasia, and in the other patient no biopsies were
obtained after 360 Express treatment.
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According to an intention-to-treat analysis, CE-D
was reached in 29/30 patients (97%) and CE-IM was
reached in 26/30 patients (87%). In a per-protocol ana-
lysis, CE-D was reached in 28/28 patients (100%) and
CE-IM in 26/28 patients (93%). One patient underwent
escape ER of residual islands (maximum 10
10mm) of non-dysplastic Barrett’s mucosa; the other
patient had IM just distal to a normal appearing neo-
squamocolumnar junction.
The median total number of treatment sessions was
three (IQR 2–4) (Table 3).
4. Number of patients with a stenosis requiring an intervention
at any time during the treatment phase Three patients
(10%) developed a stenosis after additional focal
RFA, for which they underwent endoscopic dilation
(one to two sessions). None of the patients had a
prior ER.
Discussion
This pilot study shows that c-RFA with the 360 Express
is feasible and eﬀective resulting in a median BE surface
Table 1. Definitions of outcome parameters.
Outcome parameter Definition
Percentage of endoscopically visual regression of BE
epithelium at three months.
The mean percentage of BE surface regression of the
two endoscopists who reviewed the endoscopic
images.
In case the BE regression percentage differed
30% between both endoscopists, a new score was
established during a consensus meeting.
Duration of the 360 Express procedure. 1. Total procedure time: time from the first introduc-
tion until the time of removal of the endoscope.
2. Ablation time: the period between the introduction
and the removal of the 360 Express.
Adverse events. Timing:
- acute: during the procedure
- early: 48 hours
- late: >48 hours
Severity:
- mild: unscheduled hospital admission, hospital-
ization <3 days, hemoglobin drop< 3 g/dl, no
need for transfusion.
- moderate: hospitalization 4–10 days, 4 units
blood transfusion, need for repeat endoscopic
intervention, radiological intervention.
- severe: hospitalization> 10 days, intensive care
unit admission, need for surgery, >4 units blood
transfusion; or in the case of stenosis >5 dila-
tions, stent placement, or incision therapy.
- fatal: death attributable to procedure <30 days or
longer with continuous hospitalization.6
Complete endoscopic and histological eradication of
IM at the end of the treatment phase.
Absence of visible Barrett’s epithelium at the first
follow-up endoscopy and histologically confirmed
absence of IM when biopsies were obtained during
this endoscopy.
Complete endoscopic and histological eradication of
dysplasia at the end of the treatment phase.
Absence of visible Barrett’s epithelium at the first
follow-up endoscopy and histologically confirmed
absence of dysplasia when biopsies were obtained
during this endoscopy.
Number of patients with a stenosis requiring an
intervention at any time during the treatment
phase.
Patients who developed a stenosis requiring a thera-
peutic intervention (dilation, incision therapy, stent
placement) at any point in the period from the 360
Express procedure until the first follow-up
endoscopy.
BE: Barrett’s esophagus; IM: intestinal metaplasia.
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regression of 90% three months after treatment
when using the standard ablation regimen (12 J/cm2 –
clean – 12 J/cm2).
A prior randomized clinical trial comparing diﬀerent
regimens for c-RFA using the standard system
showed that c-RFA with the standard ablation regimen
results in a median BE surface regression of 83%
(IQR 70–93) at three-month follow-up. The median
total procedure time was 39 minutes.7 The median
total procedure time in our study was 31 minutes indi-
cating that c-RFA with the 360 Express likely results in
a shorter procedure time compared with c-RFA using
the standard system.
In our study we primarily assessed the eﬃcacy of the
360 Express after a single RFA procedure by assessing
the visual surface regression of BE three months after
treatment. One may argue that obtaining biopsies
during the three-month follow-up endoscopy would
have led to more objectivity regarding the BE regres-
sion results. However, in clinical practice biopsies are
not routinely obtained after a single RFA session and
the decision to perform additional endoscopic treat-
ment is usually guided by the presence of endoscopic-
ally visible Barrett’s tissue. In our opinion, histological
conﬁrmation of absence or presence of IM does not add
enough valuable information to the assessment of high-
quality images to justify exposing patients to an extra
endoscopic procedure. In addition, in prior studies
evaluating circumferential RFA the BE regression was
assessed using endoscopic images, which allow for com-
parison.7 Since eﬃcacy of RFA is generally deﬁned as
histologically conﬁrmed complete eradication of IM or
dysplasia evaluated after multiple RFA sessions, we
additionally evaluated CE-D and CE-IM rates at the
end of the treatment phase. In this study, on an inten-
tion-to-treat basis 97% of patients achieved CE-D and
87% achieved CE-IM (per protocol: 100% and 93%,
respectively). Our ﬁndings are in line with rates
reported in the literature showing CE-IM rates ranging
from 77% to 100% and CE-D ranging from 86% to
100% of patients.1–3,8–11
In seven patients (23%) pronounced esophageal
scarring was noted during the three-month endoscopy.
However, esophageal scarring was not a prespeciﬁed
outcome and it is therefore diﬃcult to quantify. Since
none of the seven patients were symptomatic and
required an intervention, the scarring did not qualify
as stenosis. However, it was striking that all four
experienced endoscopists who participated in this
study noticed and recorded the esophageal scarring
after a single session with the 360 Express in at least
one of their patients. Upon inquiry the endoscopists
mentioned they felt there was more ﬁbrosis than what
they would expect based on their clinical experience
with the standard c-RFA system. Theoretically, the
360 Express may have a higher stenosis risk:
The system results in optimal contact between the
esophageal wall and the electrode because of the ability
to self-adjust to the EID. Compared with c-RFA using
the standard system in which the ablation catheter is
chosen based on the smallest measured EID, the entire
esophagus will receive more energy when the 360
Express is used. The use of 12 J/cm2 might therefore
result in deeper mucosal damage than when using the
traditional ablation catheter. During subsequent treat-
ment 10% of patients developed a stenosis requiring
median one dilation. Our ﬁndings are toward the high
end of the spectrum of stenosis rates after RFA
reported in the literature (0–14%).12 For follow-up stu-
dies we therefore advise an energy density setting of
10 J/cm2, as is now recommended in the instructions
for use of the 360 Express, since we believe this may
deliver a better balance of clinical eﬃcacy and safety.
There are some limitations of this study that need to
be addressed. First, this is a pilot study with a relatively
small number of patients. Second, the study was con-
ducted in four tertiary referral centers with extensive
experience in the treatment of BE. The results may
therefore not be automatically generalizable to stand-
ard clinical practice.
Table 2. Baseline characteristics.
Patients (n) 30
Male:female 24:6
Median age, years (IQR) 66 (62–73)
Median BE, cm (IQR) C 4 (2–6) M 6 (4–8)
Worst overall histological
diagnosis prior to treatment
(biopsies or ER specimens), n
LGD 14
HGD 11
EC 5
ER prior to RFA, n (%) 8 (27)
Worst histology of ER specimens, n
LGD 1
HGD 2
EC 5
Worst histological diagnosis prior to RFA
(after any ER), n
No dysplasia 2
LGD 22
HGD 6
EC 0
BE: Barrett’s esophagus; cm: centimeter; EC: early cancer; ER: endoscopic
resection; HGD: high-grade dysplasia; IQR: interquartile range; LGD: low-
grade dysplasia; min: minutes; n: number of patients; RFA: radiofrequency
ablation.
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Figure 3. Endoscopic images of esophageal scarring seen during the three-month endoscopy in four cases.
Figure 2. Endoscopic images of a circumferential ablation procedure using the 360 Express RFA balloon catheter. (a) and (b) White-light
high-resolution endoscopy (WLE) and narrow-band imaging (NBI) of a C6M10 Barrett’s esophagus with low-grade dysplasia (LGD).
(c) Deflated 360 Express balloon catheter in the esophageal lumen. (c) and (d) Ablation effect immediately after the ablation and after
removal of the catheter. (e) and (f) Effect three months later during the first post-treatment endoscopy with WLE and NBI: 97% visual
surface Barrett’s epithelium regression.
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For the standard c-RFA system, a simpliﬁed no-
cleaning ablation protocol was proven to be easier
and faster, but equally safe and eﬀective as the standard
ablation protocol.7 To evaluate if a simpliﬁed regimen
without a cleaning step is also safe when using the 360
Express, or if the stenosis risk is higher because of
deeper ablation damage in addition to heat stacking,
we initiated a randomized clinical trial (NTR5191,
www.trialregister.nl). This trial compares the standard
regimen (10 J/cm2–clean–10 J/cm2), a simpliﬁed double
regimen (2 10 J/cm2 no clean) and a simpliﬁed single
regimen (1 10 J/cm2). Although this study is still
ongoing, an interim analysis showed an unacceptably
high risk of severe stenosis (17%) in patients treated
with the 360 Express using the simpliﬁed double regi-
men, which led to early closure of this arm after con-
sultation with the data and safety monitoring board of
the study.13 The standard regimen (10 J/cm2–clean–
10 J/cm2) for the 360 Express, as advised in the instruc-
tions for use of the device, is therefore still the advised
treatment regimen.
In conclusion, the results of this pilot study show that
c-RFA with the 360 Express using an ablation regimen
of 12 J/cm2–clean–12 J/cm2 leads to a decreased pro-
cedure time, but maintains eﬃcacy and safety when
compared to c-RFA using the standard system.
Table 3. Outcomes.
Outcomes of 360 Express procedure
Patients (n) 30
Median percentage of Barrett’s surface regression at three monthsa, % (IQR) 90 (77–95)
Median total procedure time, min (IQR) 31 (28–38)
Median ablation time, min (IQR) 20 (17–25)
Adverse events of self-sizing session, n (%) 4 (13)
Mild adverse events 3
- acute laceration
- early atrial fibrillation
- late dysregulation of diabetes mellitus
Moderate complication 1
- early dysphagia, no endoscopic esophageal abnormalities
Outcomes of entire treatment phase
Patients (n) 30
Stenosis at any point during treatment phase requiring intervention, n (%) 3 (10)
Complete eradication of dysplasia at end of the treatment phase, n (%)
- Intention to treat analysis 29/30 (97)
- Per protocol analysis 28/28 (100)
Complete eradication of intestinal metaplasia at end of the treatment phase
- Intention to treat analysis 26/30 (87)
- Per protocol analysis 26/28 (93)
Median total number of treatment sessionsb per patient, (IQR) 3 (IQR 2–4)
Number of circumferential RFA sessions per patient, n 1
Median number of focal RFA sessions per patient, (IQR) 1 (1–2)
Number of patients who underwent APCc, n 13
- One session 8
- Two sessions 5
Number of patients who underwent EMR, n
- Escape treatment for residual IM after RFA (n¼ 1) 2
- Diagnosis of elevated BE islands (n¼ 1)d
aMean of two independent scores by expert endoscopists.
bTreatment sessions included circumferential RFA, focal RFA, APC and EMR.
cAPC was used to treat small areas of Barrett’s mucosa (islands/tongues< 10mm).
dHistology showed non-dysplastic IM.
APC: argon plasma coagulation; BE: Barrett’s esophagus; EMR: endoscopic mucosal resection; IM: intestinal metaplasia;
IQR: interquartile range; min: minutes; n: number of patients; RFA: radiofrequency ablation.
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Potentially, better contact of the electrode may result
in more ablation damage to the esophageal wall,
resulting in more scarring, and an ablation regimen
with a lowered energy setting (10 J/cm2–clean–
10 J/cm2) is therefore currently advised for RFA using
the 360 Express.
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Appendix A
Details on the BarrxTM 360 Express RFA balloon
catheter
The 360 Express consists of a 4 cm long bipolar elec-
trode array that is wrapped around a balloon. The
Barrx Flex energy generator delivers radiofrequency
energy in a bipolar mode to the balloon device. After
placement over a guide wire, the device is inﬂated under
endoscopic control, to a set pressure via the Barrx Flex
energy generator. As the balloon inﬂates, the electrode
unwraps until the electrode contacts the esophageal
wall (ﬁgure 1). Upon activation with a foot paddle,
energy is delivered using the identical energy algorithms
(12 J/cm2, 40W/cm2) as with the standard RFA
Balloon Catheter, leading to controlled depth ablation
Belghazi et al. 9
of the Barrett’s epithelium. After the ablation is com-
plete, the generator automatically deﬂates the device
causing the electrode to rewrap to its pre-expanded
diameter. The Barrx Flex energy generator and the
360 Express have a CE mark for use in Europe.
Appendix B
Details on the four adverse events that occurred after a
single 360 Express procedure.
Acute adverse event
A 2 cm long mucosal laceration just above the top of
the gastric folds occurred during the ﬁrst ablation pass
in one patient. The zone proximal to the laceration was
ablated for the second time according to protocol; the
area with the laceration was not treated a second time.
The laceration healed uneventfully and during the
three-month follow-up no scarring was observed at
the site of the laceration. The estimated regression per-
centage was 90%.
Early adverse events
A 65-year-old male developed asymptomatic atrial
ﬁbrillation after the RFA procedure, for which he
was referred to a cardiologist. It was unclear whether
this was a preexisting condition.
A 59-year-old female experienced dysphagia and
vomiting one day after the procedure. She presented
to the emergency room ﬁve days after RFA treatment
and was hospitalized. Gastroscopy showed an ulcerated
esophagus as expected after recent RFA treatment,
without any signs of stenosis. A temporary duodenal
feeding tube was placed; the patient recovered and was
discharged home eight days later.
Late adverse event
One patient with known diabetes was hospitalized with
dysregulation of glucose levels four days after the RFA
procedure. She recovered after she was put on a new
insulin regimen and was discharged after three days.
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